The American Society of Health-System Pharmacists (ASHP) has endorsed the CPIC guidelines for CYP2C19 genotype and clopidogrel therapy, published in Clinical Pharmacology and Therapeutics.
In their report, they highlight that the guidelines address an important need for information on the clinical application of pharmacogenomic testing and appreciate that the recommendations are based on interpretation of genetic test results and not whether a genetic test should be carried out or not.
Read the CYP2C19-clopidogrel CPIC therapeutic guidelines on PharmGKB
See more pharmacogenetic-based drug dosing guidelines published by CPIC
Read the ASHP reports on the ASHP website